🚀 VC round data is live in beta, check it out!
Akums Drugs and Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Akums Drugs and Pharma and similar public comparables like Gen İlaç, Polaris Group, Nika Pharmaceuticals, KalVista Pharmaceuticals and more.
Akums Drugs and Pharma Overview
About Akums Drugs and Pharma
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).
Founded
2004
HQ
Employees
17.9K
Website
Financials (LTM)
EV
$624M
Akums Drugs and Pharma Financials
Akums Drugs and Pharma reported last 12-month revenue of $476M and EBITDA of $56M.
In the same LTM period, Akums Drugs and Pharma generated $201M in gross profit, $56M in EBITDA, and $29M in net income.
Revenue (LTM)
Akums Drugs and Pharma P&L
In the most recent fiscal year, Akums Drugs and Pharma reported revenue of $484M and EBITDA of $58M.
Akums Drugs and Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $476M | XXX | $484M | XXX | XXX | XXX |
| Gross Profit | $201M | XXX | $175M | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $56M | XXX | $58M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $29M | XXX | $38M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 8% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Akums Drugs and Pharma Stock Performance
Akums Drugs and Pharma has current market cap of $797M, and enterprise value of $624M.
Market Cap Evolution
Akums Drugs and Pharma's stock price is $5.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $624M | $797M | 0.4% | XXX | XXX | XXX | $0.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAkums Drugs and Pharma Valuation Multiples
Akums Drugs and Pharma trades at 1.3x EV/Revenue multiple, and 11.2x EV/EBITDA.
EV / Revenue (LTM)
Akums Drugs and Pharma Financial Valuation Multiples
As of March 7, 2026, Akums Drugs and Pharma has market cap of $797M and EV of $624M.
Equity research analysts estimate Akums Drugs and Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Akums Drugs and Pharma has a P/E ratio of 27.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $797M | XXX | $797M | XXX | XXX | XXX |
| EV (current) | $624M | XXX | $624M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 11.2x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBIT | 16.2x | XXX | 17.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | 3.6x | XXX | XXX | XXX |
| P/E | 27.0x | XXX | 20.9x | XXX | XXX | XXX |
| EV/FCF | 29.6x | XXX | 29.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Akums Drugs and Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Akums Drugs and Pharma Margins & Growth Rates
Akums Drugs and Pharma's revenue in the last 12 month grew by 12%.
Akums Drugs and Pharma's revenue per employee in the last FY averaged $0.0M.
Akums Drugs and Pharma's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Akums Drugs and Pharma's rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Akums Drugs and Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | (4%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Akums Drugs and Pharma Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gen İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Polaris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Nika Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| KalVista Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Janux Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akums Drugs and Pharma M&A Activity
Akums Drugs and Pharma acquired XXX companies to date.
Last acquisition by Akums Drugs and Pharma was on XXXXXXXX, XXXXX. Akums Drugs and Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Akums Drugs and Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAkums Drugs and Pharma Investment Activity
Akums Drugs and Pharma invested in XXX companies to date.
Akums Drugs and Pharma made its latest investment on XXXXXXXX, XXXXX. Akums Drugs and Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Akums Drugs and Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Akums Drugs and Pharma
| When was Akums Drugs and Pharma founded? | Akums Drugs and Pharma was founded in 2004. |
| Where is Akums Drugs and Pharma headquartered? | Akums Drugs and Pharma is headquartered in India. |
| How many employees does Akums Drugs and Pharma have? | As of today, Akums Drugs and Pharma has over 17K employees. |
| Is Akums Drugs and Pharma publicly listed? | Yes, Akums Drugs and Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Akums Drugs and Pharma? | Akums Drugs and Pharma trades under AKUMS ticker. |
| When did Akums Drugs and Pharma go public? | Akums Drugs and Pharma went public in 2024. |
| Who are competitors of Akums Drugs and Pharma? | Akums Drugs and Pharma main competitors are Gen İlaç, Polaris Group, Nika Pharmaceuticals, KalVista Pharmaceuticals. |
| What is the current market cap of Akums Drugs and Pharma? | Akums Drugs and Pharma's current market cap is $797M. |
| What is the current revenue of Akums Drugs and Pharma? | Akums Drugs and Pharma's last 12 months revenue is $476M. |
| What is the current revenue growth of Akums Drugs and Pharma? | Akums Drugs and Pharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Akums Drugs and Pharma? | Current revenue multiple of Akums Drugs and Pharma is 1.3x. |
| Is Akums Drugs and Pharma profitable? | Yes, Akums Drugs and Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Akums Drugs and Pharma? | Akums Drugs and Pharma's last 12 months EBITDA is $56M. |
| What is Akums Drugs and Pharma's EBITDA margin? | Akums Drugs and Pharma's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Akums Drugs and Pharma? | Current EBITDA multiple of Akums Drugs and Pharma is 11.2x. |
| What is the current FCF of Akums Drugs and Pharma? | Akums Drugs and Pharma's last 12 months FCF is $21M. |
| What is Akums Drugs and Pharma's FCF margin? | Akums Drugs and Pharma's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Akums Drugs and Pharma? | Current FCF multiple of Akums Drugs and Pharma is 29.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.